KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $495.5 million.

  • Sarepta Therapeutics' Operating Expenses rose 3626.8% to $495.5 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 211.13%. This contributed to the annual value of $1.7 billion for FY2024, which is 1143.08% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Operating Expenses stood at $495.5 million, which was up 3626.8% from $600.0 million recorded in Q1 2025.
  • In the past 5 years, Sarepta Therapeutics' Operating Expenses ranged from a high of $600.0 million in Q1 2025 and a low of $223.9 million during Q3 2021
  • Moreover, its 5-year median value for Operating Expenses was $368.7 million (2022), whereas its average is $384.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 2033.08% in 2021, then soared by 6153.74% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Operating Expenses (Quarter) stood at $307.3 million in 2021, then rose by 18.87% to $365.3 million in 2022, then increased by 1.89% to $372.2 million in 2023, then skyrocketed by 33.47% to $496.7 million in 2024, then dropped by 0.25% to $495.5 million in 2025.
  • Its Operating Expenses stands at $495.5 million for Q2 2025, versus $600.0 million for Q1 2025 and $496.7 million for Q4 2024.